Thyroid Eye Disease Plasma
Thyroid Eye Disease Plasma is collected from IRB-consented donors with clinically confirmed TED, a Graves'-associated autoimmune orbital disease involving TSHR and IGF-1R signalling in orbital fibroblasts. Suitable for TSHR autoantibody and thyroid-stimulating immunoglobulin measurement, cytokine profiling, and disease-activity biomarker research. Available stratified by active versus fibrotic phase and treatment status, with matched healthy controls.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 69462 | Thyroid Eye Disease | 1.0 ML | Caucasian | 55 | Female | United States |
Synthroid QD Zetia QD Protonix QD Allegra D QD Lunesta prn Gabapentin QD Flexeril Nightly
|
15 | $667.00 | |
| 70181 | Thyroid Eye Disease | 1.0 ML | Caucasian | 77 | Male | United States |
Tepezza Methimazole QD M-F Losartan 25mg QD Atorvastatin 20mg QD Sertraline QD Finasteride 1mg QD
|
13 | $667.00 | |
| 69341 | Thyroid Eye Disease | 1.0 ML | Caucasian | 46 | Female | United States |
Levothyroxine .112, GLP-1, magnesium, Tepezza Synthroid 112 mcg QD Phentermine 37.5 mg QD Celebrex 100 mg PRN Refresh eye drops PRN Systane eye drops PRN
|
15 | $667.00 | |
| 69370 | Thyroid Eye Disease | 1.0 ML | African American | 57 | Female | United States |
Synthroid 88 mcg QD Sertraline 50mg QD Zyrtec OTC QD Amlodipine 10 mg QD
|
17 | $667.00 | |
| 69444 | Thyroid Eye Disease | 1.0 ML | Caucasian | 53 | Female | United States |
Synthroid, colanzepin depakote metoprolol vraylar
|
12 | $667.00 | |
| 69369 | Thyroid Eye Disease | 1.0 ML | Caucasian | 58 | Female | United States |
Levothyroxine Prescribed eye drops
|
14 | $667.00 |
Thyroid Eye Disease Plasma for Autoimmune Orbital Disease Research
Thyroid Eye Disease Plasma is collected from IRB-consented donors clinically diagnosed with thyroid eye disease (TED) and processed within one day of collection to preserve cytokines, autoantibodies, proteins and metabolites. Plasma is acellular, so this product is intended for soluble-analyte measurement rather than cell-based assays.
TED Autoimmunity and Why Plasma
Thyroid eye disease is an autoimmune orbital condition, in the great majority of cases occurring in association with Graves’ disease. The orbit, not the thyroid, is the site of the pathology.
- Stimulating autoantibodies against the thyrotropin receptor (TSHR), the same autoantibodies that cause Graves’ hyperthyroidism, are central to the disease and are detectable in circulation
- Orbital fibroblasts express TSHR and IGF-1R, and functional crosstalk between these receptors is the mechanistic basis for IGF-1R-directed therapy in TED
- Activated orbital fibroblasts secrete hyaluronan and a subset differentiate into adipocytes, expanding orbital soft tissue volume and producing proptosis and, in severe cases, optic neuropathy
- An active inflammatory phase precedes a stable fibrotic phase, and clinical activity scoring is used to distinguish them; treatment strategy differs between the two
- TSHR autoantibody levels, IGF-1 and inflammatory cytokines are all measurable in plasma, supporting non-invasive activity and treatment-response research without orbital biopsy
- Plasma supports autoantibody immunoassays, multiplex cytokine panels, proteomics and metabolomics from a single acellular sample
Donor Stratification Available
- Active inflammatory phase versus stable or fibrotic phase
- Clinical activity or severity grade where documented
- TSHR autoantibody status and titre where available
- Underlying thyroid status: hyperthyroid, euthyroid on treatment, or hypothyroid post-treatment
- Treatment status: treatment-naive, on corticosteroids, on IGF-1R-directed biologic therapy, or post-orbital surgery or radiotherapy
- Smoking status, an established risk factor for progression
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed Thyroid Eye Disease donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
- Anticoagulant selection available on request to match your assay
De-identified Donor Data
- Verified Thyroid Eye Disease diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Thyroid function and autoantibody results where available
- Additional thyroid eye disease-specific metadata available
Applications
- TSHR autoantibody and thyroid-stimulating immunoglobulin quantification
- IGF-1 and IGF-1R pathway soluble marker measurement
- Inflammatory cytokine and chemokine profiling
- Disease activity biomarker discovery and validation
- Fibrosis and extracellular matrix turnover marker measurement
- Plasma proteomics and metabolomics in orbital autoimmune disease
- Biologic therapy pharmacodynamic and treatment-response research
- Autoantibody immunoassay development against matched controls
Other Thyroid Eye Disease Specimen Types
- Thyroid Eye Disease Serum
- Thyroid Eye Disease Whole Blood
- Thyroid Eye Disease PBMC
- Graves’ Disease Serum
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Thyroid Eye Disease plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse plasma from other disease states and check live stock status, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.